CLINICAL TRIALS
Active clinical trials and verified researcher listings for Sickle Cell Disease, simplified into plain English.
ABOUT SICKLE CELL DISEASE
Sickle cell disease (SCD), also simply called sickle cell is a group of inherited hemoglobin-related blood disorders. The most common type is known as sickle cell anaemia. Sickle cell anaemia results in an abnormality in the oxygen-carrying protein haemoglobin found in red blood cells. This leads to the red blood cells adopting an abnormal sickle-like shape under certain circumstances. With this shape, they cannot deform as they pass through capillaries, causing blockages.
Source: Wikipedia. For educational use only — not medical advice.
ACTIVELY RECRUITING TRIALS
COMMON QUESTIONS
Are there clinical trials currently recruiting for Sickle Cell Disease?
Yes. This page displays actively recruiting Sickle Cell Disease clinical trials sourced in real time from ClinicalTrials.gov. Use the filters to narrow by phase, status, and location.
How do I join a clinical trial for Sickle Cell Disease?
Browse the trials listed above, review the eligibility criteria for each study, and submit a contact request directly to the research team. You can also speak to your physician about a referral.
Are Sickle Cell Disease clinical trials free to participate in?
Most clinical trials cover the cost of the investigational treatment and all study-related visits. Some studies also offer compensation for time and travel. Always confirm costs and insurance coverage with the trial coordinator before enrolling.
What eligibility requirements apply to Sickle Cell Disease trials?
Requirements vary by study. Common criteria include a confirmed Sickle Cell Disease diagnosis, age range, prior treatments, and general health status. Each trial listing shows its specific inclusion and exclusion criteria.
What phases of Sickle Cell Disease trials are available?
Sickle Cell Disease trials span Phase I (safety testing), Phase II (effectiveness), Phase III (comparison to standard care), and Phase IV (post-approval monitoring). Phase II and III trials are most commonly open to new participants.